|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The ASPL-TFE3 fusion replaces the N-terminal portion of TFE3 by the fused ASPL sequences, while retaining the TFE3 DNA-binding domain, implicating transcriptional deregulation in the pathogenesis of this tumor, consistent with the biology of several other translocation-associated sarcomas.Oncogene (2001) 20, 48 - 57.
|
11244503 |
2001 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.
|
11438465 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The most distinctive immunohistochemical feature of these neoplasms was moderate to intense nuclear labeling for TFE3 protein.
|
12459622 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Four genes in our study were CMRI-H and could thus possibly play a role in the development of MSI-H tumors: TFE3 (9/38), TEF4 (12/38), RGS12 (11/38), and TCF1 (12/38).
|
12461749 |
2003 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Renal carcinomas associated with Xp11.2 translocations that result in fusions involving the TFE3 transcription factor gene have been delineated, including a distinctive neoplasm that shares the identical gene fusion as alveolar soft part sarcoma.
|
12973047 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, only 6 of 1476 other neoplasms labeled for TFE3 (sensitivity 97.5%, specificity 99.6%).
|
12766578 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Reverse transcriptase-polymerase chain reaction (RT-PCR) and sequence analysis demonstrated reciprocal ASPL-TFE3 and TFE3-ASPL fusion transcripts in the retroperitoneal tumor, cultured FU-UR-1 cells and xenografted tumors.
|
15138551 |
2004 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The large proportion of TFE3 "translocation" carcinomas and "unclassified" carcinomas in the first two decades of life demonstrates that renal cell carcinomas in young patients contain genetically and phenotypically distinct tumors with further potential for novel renal cell carcinoma subtypes.
|
15316311 |
2004 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We report the case of a 58-year old patient, showing a solid image in the right kidney, who underwent radical nephrectomy that revealed neoplasia, whose pathological study led to the diagnosis of kidney carcinoma associated with Xp11.2 translocation / TFE3 (ASPL-TFE3) gene fusion.
|
15992428 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor showed nuclear labeling for TFE3 protein by immunohistochemistry, supporting the above diagnosis.
|
16807766 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
(4) One patients with a TFE3+ and MITF+ tumor and 66-87,XXY,der(1)t(1;8)del(4)(q?) der(11)t(11;15)der17t(X;17 abnormalities died 9 months after diagnosis.
|
16880148 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We examined a cohort of patients with alveolar soft part sarcoma (ASPS) treated at our institution and showed the characteristic ASPSCR1-TFE3 fusion transcript in their tumors.
|
18094412 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
No expression of ASPL-TFE3 fusion transcripts was detectable in all 38 control tumors.
|
18382356 |
2008 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Oxalate crystal deposition was observed in the stroma and the tumor focally resembled translocation type (TFE3) RCC.
|
18785115 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
None of the 14 neoplasms showed immunoreactivity for TFE3.
|
18779729 |
2008 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
One tumor, currently at passage 6, has been maintained in vivo for 32 months and has maintained characteristics consistent with those of the original ASPS tumor including (1) tumor histology and staining with periodic acid Schiff/diastase, (2) the presence of the ASPL-TFE3 type 1 fusion transcript, (3) nuclear staining with antibodies to the ASPL-TFE3 type 1 fusion protein, (4) maintenance of the t(X;17)(p11;q25) translocation characteristic of ASPS, (5) stable expression of signature ASPS gene transcripts and finally, the development and maintenance of a functional vascular network, a hallmark of ASPS.
|
19636271 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical evaluation revealed that the tumor cells showed nuclear labeling for TFE3 protein.
|
19298350 |
2009 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The morphologic and immunohistochemical discrepancies between this intriguing melanotic tumor and other documented renal cell carcinomas bearing identical PSF-TFE3 gene fusion may suggest melanotic Xp11 translocation renal cancer is a distinct entity among the MiT/TFE family neoplasms.
|
19809274 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of the present study was to figure out in two pediatric RCC recently diagnosed in our department (one clear cell-type RCC and one TFE3-positive RCC) whether those features are indeed specific of the latter tumor or occur in pediatric RCC irrespective of the tumor type.
|
19246164 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
(3) These results further support the concept that the overexpression of TFE3 or TFEB in these neoplasms activates the expression of genes normally regulated by microphthalmia transcription factor in other cell types.
|
19396149 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These neoplasms represent the first documented examples in which TFE3 gene fusions coexist with melanin production, and their identification raises the possibility that TFE3 gene fusions may underlie an aggressive subset of lesions currently classified as PEComa in young patients.
|
19065101 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These epithelioid cells were immunohistochemically positive for vimentin, gp100 (detected with monoclonal antibody HMB-45), and TFE3, and the tumor was diagnosed as PEComa.
|
19606011 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TFE3 and Cathepsin K remain the most sensitive and specific markers of these neoplasms.
|
20679884 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, aberrant immunoreactivity for TFE3 protein (a sensitive and specific marker of neoplasms harboring TFE3 gene fusions) has been reported in as many as 100% of PEComas; however, TFE3 gene status in these neoplasms has not been systematically investigated.
|
20871214 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Diagnostic tools to detect translocations involving the TFE3 gene on chromosome X would be valuable in the evaluation of these tumors.
|
20421778 |
2010 |